News & Updates

Show Multimedia Only
Dapagliflozin safe, effective in HF patients across global regions

Dapagliflozin safe, effective in HF patients across global regions

08 Sep 2023 byStephen Padilla

Dapagliflozin for individuals with heart failure (HF) demonstrates consistent safety and efficacy across regions worldwide despite geographic differences in patient characteristics, background treatment, and event rates, reports a recent study.

Dapagliflozin safe, effective in HF patients across global regions

08 Sep 2023
Depression ups risk of CVD, mortality

Depression ups risk of CVD, mortality

08 Sep 2023 byStephen Padilla

Individuals with depression are at higher risk of developing cardiovascular disease (CVD), which may even result in death, suggests a recent study.

Depression ups risk of CVD, mortality

08 Sep 2023
Heart failure, death risks elevated within 10 years after myocardial infarction

Heart failure, death risks elevated within 10 years after myocardial infarction

04 Sep 2023 byStephen Padilla

Nearly one in three patients with myocardial infarction (MI) develop heart failure or renal failure, while a few of them experience another MI or, worse, die within 10 years, according to a study in England.

Heart failure, death risks elevated within 10 years after myocardial infarction

04 Sep 2023